Aditya Mangla, DO
Interventional Cardiology · Richmond Hill, NYNPI 1548453285
Payments from drug & device makers
Across 543 payments — averaging $146.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$21K
- Inari Medical, Inc.$14K
- Shockwave Medical, Inc$12K
- Bard Peripheral Vascular, Inc.$5K
- Penumbra, Inc.$5K
- Abiomed$4K
- plus $18K from 31 others
What the payments were for
- Consulting fees$7,0009%
- Speaking & faculty fees$6,6009%
- Travel & lodging$23,26931%
- Food & beverage$37,34650%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 108 | $20,890 |
| Inari Medical, Inc. | 39 | $13,756 |
| Shockwave Medical, Inc | 48 | $12,316 |
| Bard Peripheral Vascular, Inc. | 2 | $5,148 |
| Penumbra, Inc. | 15 | $4,887 |
| Abiomed | 44 | $4,136 |
| Abbott | 77 | $3,786 |
| Boston Scientific | 59 | $3,773 |
| Cardiovascular Systems Inc. | 49 | $2,518 |
| Endologix LLC | 4 | $1,527 |
| Philips North America LLC | 23 | $1,453 |
| Teleflex LLC | 8 | $814 |
| Angiodynamics, Inc. | 6 | $511 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $488 |
| Acist Medical Systems, Inc. | 9 | $440 |
| ZOLL Circulation Inc | 2 | $352 |
| Spectrawave, Inc | 2 | $229 |
| Heartflow, Inc. | 2 | $209 |
| Cordis US CORP. | 1 | $205 |
| Terumo Medical Corporation | 4 | $159 |
| Cvrx, Inc. | 2 | $155 |
| Arrow International, Inc. | 2 | $148 |
| Johnson & Johnson | 3 | $145 |
| Saranas, Inc. | 1 | $143 |
| Siemens Medical Solutions USA, Inc. | 1 | $143 |
| Endotronix, Inc. | 1 | $135 |
| Biotronik Inc. | 1 | $133 |
| Bolton Medical Inc | 1 | $131 |
| Z-medica, LLC | 1 | $129 |
| Novo Nordisk | 1 | $110 |
| Pfizer | 4 | $87 |
| Alnylam Pharmaceuticals Inc. | 1 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $85 |
| AstraZeneca | 4 | $54 |
| Kestra Medical Technology Services, Inc. | 1 | $50 |
| Novartis | 1 | $18 |
| Argon Medical Devices, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$12,941
- CT THROMBECTOMY SYSTEM KIT$12,508
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$11,172
- Indigo System$4,803
- Impella$3,050
- Resolute$2,393
- ENDOCROSS Device$1,444
- Torus Stent Graft System$1,444
- Coronary Orbital Atherectomy System$1,002
- AVVIGO Guidance System$977
- Xience V coronary stent system$773
- MANTA$677
- Peripheral Orbital Atherectomy System$591
- SYNERGY$584
- GENERAL - STENTS$534
- US Und$419
- ONYX FRONTIER$407
- Vascular Lithotripsy$398
- SYMPLICITY G3$392
- Diamondback Coronary$372
How this compares
$79,362 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 63 | $77,575 |
| EliquisApixaban | 65 | $54,346 |
| BrilintaTicagrelor | 35 | $29,790 |
| FarxigaDapagliflozin Propanediol | 21 | $26,678 |
| JardianceEmpagliflozin | 15 | $20,043 |
| XareltoRivaroxaban | 17 | $18,283 |
| Ranolazine ErRanolazine | 39 | $2,920 |
| Atorvastatin Calcium | 222 | $2,341 |
| Metoprolol Succinate | 118 | $1,761 |
| ClopidogrelClopidogrel Bisulfate | 170 | $1,759 |
| Carvedilol | 101 | $952 |
| Labetalol Hcl | 16 | $711 |
| Nebivolol Hcl | 16 | $704 |
| Losartan Potassium | 67 | $702 |
| Amlodipine Besylate | 103 | $634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $18 | $77,57563 claims |
| AstraZenecaBrilinta, Farxiga | $54 | $56,46756 claims |
| PfizerEliquis | $87 | $54,34665 claims |
| Johnson & JohnsonXarelto | $145 | $18,28317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Richmond Hill
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.